Is it possible to improve prognosis in patients with chronic obstructive pulmonary disease?
https://doi.org/10.18093/0869-0189-2015-25-4-469-476
Abstract
According to reports of World Health Organization, chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death worldwide. Near 2.8 million patients die from COPD yearly, this is 4.8% of all deaths in the world. Causes of death in COPD patients include respiratory causes, acute exacerbation of COPD in 50–80% of cases, lung carcinoma in 8.5 to 27% and other non respiratory causes. Key predictors of poor prognosis of COPD include age, severity of bronchial obstruction and of lung hyperinflation, hypoxemia and hypercapnia, frequent exacerbations, comorbidity, etc. Long term oxygen therapy (for hypoxemic patients), non invasive ventilation (for hypercapnic patients), lung transplantation (for patients with end stage of COPD), and novel bronchodilators (tiotropium bromide) are therapeutic modalities that could decrease mortality, improve lung function and reduce number of exacerbations.
About the Author
S. N. Avdeev
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Clinical Department, Federal Institution "Pulmonology Research Institute", Federal Medical and Biological Agency of Russia; tel. / fax: (495) 4655264
References
1. Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projection. Eur. Respir. J. 2006; 27: 397–412.
2. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
3. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet. 2007; 370: 741–750.
4. Жестков А.В., Косарев В.В., Бабанов С.А., Глазитов А.В. Эпидемиология и факторы риска хронической обструктивной болезни легких в крупном промышленном центре Среднего Поволжья. Профилактика заболеваний и укрепление здоровья. 2009; 1: 42–44. / Zhestkov A.V., Kosarev V.V., Babanov S.A., Glazitov A.V. Epidemiology and risk factors of chronic obstructive pulmonary disease in a large industrial center of the Middle Volga region. Profilaktika zabolevaniy i ukreplenie zdorov'ya. 2009; 1: 42–44 (in Russian).
5. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Intern. J. COPD. 2014; 9: 963–974.
6. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2015 report is available on www.goldcopd.com
7. Hoyert D.L., Xu J. Deaths: preliminary data for 2011. Natl. Vital. Stat. Rep. 2012; 61: 1–51.
8. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971–2000. MMWR Surveillance Summaries. 2002; 51 (SS06): 1–16.
9. Burney P.G.J., Patel J., Newson R. et al. Global and region al trends in COPD mortality, 1990–2010. Eur. Respir. J. 2015; 45: 1239–1247.
10. Garcia I.S., Clarа P.C. Causes of death and prediction of mortality in COPD. Arch. Bronconeumol. 2010; 46: 343–346.
11. Fuso L., Incalzi R.A., Pistelli R. et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am. J. Med. 1995; 98: 272–277.
12. Vestbo J., Prescott E., Lange P. et al. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir. Med. 1998; 92: 772–776.
13. Hansen E.F., Phanareth K., Laursen L.C. et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1267–1271.
14. Martinez F.J., Foster G., Curtis J.L. et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am. J. Respir. Crit. Care Med. 2006; 173: 1326–1334.
15. Ries A.L., Kaplan R.M., Limberg T.M., Prewitt L.M. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann. Intern. Med. 1995; 122: 823–832.
16. Anthonisen N.R., Wright E.C., Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis.1986; 133: 14–20.
17. Tantucci C., Donati P., Nicosia F. et al. Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir. Med. 2008; 102: 613–619.
18. Casanova C., Cote C., de Torres J.P. et al. Inspiratory to total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591–597.
19. Boushy S.F., Coates E.D., Prognostic valie of pulmonary function tests in emphysema: with special reference to arterial blood studies. Am. Rev. Respir. Dis. 1964; 90: 553–563.
20. Kanner R.E., Renzetti A.D., Stanish W.M. et al. Predictors of survival in subjects with chronic airflow limitation. Am. J. Med. 1983; 74: 249–255.
21. Nizet T.A.C., van den Elshout F.J.J., Heijdra Y.F. et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005; 127: 1904–1910.
22. Cooper C.B., Waterhouse J., Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax. 1987; 42: 105–110.
23. Ahmadi Z., Bornefalk Hermansson A., Franklin K.A. et al. Hypo and hypercapnia predict mortality in oxygen dependent chronic obstructive pulmonary disease: a population based prospective study. Respir. Res. 2014, 15: 30.
24. Burrows B., Kettel L.J., Niden A.H., Rabinowitz M., Diener C.F. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med. 1972; 286: 912–918.
25. Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.
26. Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.
27. Schols A.M., Slangen J., Volovics L.,Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791–1797.
28. Landbo C., Prescott E., Lange P., Vestbo J., Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1856–1861.
29. Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003; 167: 544–549.
30. Soler Cataluna J.J., Martinez Garcia M.A., Roman S.P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925–931.
31. Suissa S., Dell'aniello S., Ernst P. Long term natural history of chronic obstructive pulmonary disease: severe exacer bations and mortality. Thorax. 2012; 67: 957–963.
32. Divo M., Cote C., de Torres J.P. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186:155–161.
33. Engstrom G., Lind P., Hedblad B. et al. Lung function and cardiovascular risk: relationship with inflammation sensitive plasma proteins. Circulation. 2002; 106: 2555–2560.
34. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation. 2003; 107: 1514–1519.
35. Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med. 2015; 109: 785–802.
36. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
37. Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1 year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274: 1852–1857.
38. Almagro P., Calbo E., Ochoa de Echaguen A. et al. Mortality after hospitalization for COPD. Chest. 2002; 121: 1441–1448.
39. Connors A.F., Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.
40. Wouters E.F. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.
41. Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J. 2005; 26: 234–241.
42. Kong G.K., Belman M.J., Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest. 1997; 111: 89–94.
43. Boushy S.F., Coates E.D., Prognostic valie of pulmonary function tests in emphysema: with special reference to arterial blood studies. Am. Rev. Respir. Dis. 1964; 90: 553–563.
44. Kanner R.E., Renzetti A.D., Stanish W.M. et al. Predictors of survival in subjects with chronic airflow limitation. Am. J. Med. 1983; 74: 249–255.
45. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981; i: 681–686.
46. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.
47. McEvoy R.D., Pierce R.J., Hillman D. et al. Nocturnal non invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009; 64: 561–566.
48. Kóhnlein T., Windisch W., Kóhler D. et al. Non invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir. Med. 2014; 2: 698–705.
49. Lahzami S., Bridevaux P.O., Soccal P.M. et al. Survival impact of lung transplantation for COPD. Eur. Respir. J. 2010; 36: 74–80.
50. Short P.M., Williamson P.A., Elder D.H. et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long acting β agonist therapy in COPD. Chest. 2012; 141: 81–86.
51. Tashkin D.P., Celli B., Senn S. et al. A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.
52. Celli B., Decramer M., Leimer I. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010; 137; 20–30.
53. Neff A.L., Petty T.A. Long term continuous oxygen therapy in chronic airway obstruction: mortality in relation to corpulmonale, hypoxia and hypercapnia. Ann. Intern. Med. 1970; 72: 621–626.
54. Elliot M.W. Non invasive ventilation in chronic obstructive pulmonary disease. In: Simonds A.K., ed. Non Invasive Respiratory Support, 3rd ed. London: Hodder Arnold; 2007.
55. Leger P., Bedicam J.M., Cornette A. et al. Nasal intermittent positive pressure ventilation. Long term follow up in patients with severe chronic respiratory insufficiency. Chest. 1994; 105: 100–105.
56. Strumpf D.A., Millman R.P., Carlisle C.C. et al. Nocturnal positive pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1991; 144: 1234–1239.
57. Marin J.M., Soriano J.B., Carrizo S.J. et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir. Crit. Care Med. 2010; 182: 325–331.
58. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364: 709–721.
59. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948–1953.
60. Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.
61. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–1909.
62. Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115–1119.
63. Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.
64. Yohannes A.M., Connolly M., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 117–125.
65. Gershon A.S., Wang L., To T. et al. Survival with tiotropium compared to long acting beta 2 agonists in chronic obstructive pulmonary disease. J. COPD. 2008; 5: 229–234.
66. Lipworth B.J., Short P.M. Explaining differential effects of tiotropium on mortality in COPD. Thorax. 2013; 68: 589–590.
67. Jenkins C.R., Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 5–7.
68. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat Inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501.
Review
For citations:
Avdeev S.N. Is it possible to improve prognosis in patients with chronic obstructive pulmonary disease? PULMONOLOGIYA. 2015;25(4):469-476. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-4-469-476
Views:
36305
Email this article 